Safety and Efficacy of Empagliflozin (Jardiance) in Adults with Diabetes

Indications Recommended by Professional Guidelines

The American Diabetes Association (ADA) 2025 guideline strongly recommends SGLT2 inhibitors such as empagliflozin for adults with type 2 diabetes who have (1) established cardiovascular disease, (2) heart failure, or (3) chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) > 20 mL/min/1.73 m²; the recommendation is independent of A1C level and may be used with or without metformin. Strength of evidence: strong recommendation (Grade A). 1

Empagliflozin may be initiated in patients with an eGFR ≥ 20 mL/min/1.73 m² when the indication is heart failure or cardiovascular risk; however, glycemic efficacy declines when eGFR falls below 45 mL/min/1.73 m², while cardiovascular and renal protective effects remain. Strength of evidence: guideline‑based clinical recommendation. 1
Monitoring of renal function should be performed periodically because the glucose‑lowering effect wanes below an eGFR of 45 mL/min/1.73 m², yet the drug’s cardio‑renal benefits persist. Strength of evidence: guideline‑based recommendation. 1

Empagliflozin carries a serious risk of (euglycemic) DKA, which can occur even when blood glucose is < 250 mg/dL.
The drug should be temporarily discontinued during major surgery to mitigate DKA risk. Strength of evidence: clinical precaution from guideline literature. 1

Patients receiving diuretics are at increased risk of volume depletion when treated with empagliflozin; clinicians should assess volume status and correct any depletion before initiation. Strength of evidence: guideline‑based safety warning. 1

Empagliflozin provides cardiovascular and renal protection that extends beyond its glucose‑lowering effect, making it a preferred therapeutic option even in patients who have already achieved glycemic targets. Strength of evidence: strong recommendation (based on multiple large outcome trials). 1
The Lancet Diabetes & Endocrinology (2021) corroborates these benefits, highlighting reduced heart‑failure hospitalization and slowed CKD progression in diverse patient populations. Strength of evidence: high‑quality randomized trial data. 3